• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
BOT

BOTANIX PHARMACEUTICALS LTD - News & Media

0.00% ! 14.5¢
Market Cap $284.3M  !
Healthcare Biotechnology
Add to My Watchlist

Botanix (ASX:BOT) is an ASX-listed dermatology company based in Philadelphia and Phoenix... Botanix (ASX:BOT) is an ASX-listed dermatology company based in Philadelphia and Phoenix (USA), committed to the development of novel treatments for common skin diseases and infections.More

Articles & Videos

Maybe sweat the small stuff: Botanix underwhelms, falls -40%

The problem with building big valuation expectations on the treatment of rare diseases is that you either need expensive drugs, or, some kind of government support, because a rare disease, by its very nature, implies a small addressable market.Listen to the HotCopper podcast for in-depth discussi...

08 Jul 2025 11:22 (AEST)

First Sofdra prescriptions for excessive sweating condition pushes Botanix towards full commercial launch

Botanix has reported the first prescriptions of its drug Sofdra (sofpironium) to treat hyperhidrosis, a condition of excessive sweating.

17 Dec 2024 10:25 (AEDT)

US FDA approves Botanix Pharma's excessive underarm sweat drug

Botanix on Thursday described itself as having transitioned from a development stage to being revenue-generating dermatology company.

20 Jun 2024 10:56 (AEST)

Botanix isn't sweating on FDA approval for Sofdra

Botanix has submitted the last label materials to the FDA seeking approval for Sofdra™ a prescription treatment for underarm sweating.

12 Jun 2024 09:49 (AEST)

Botannix Pharmaceuticals' resubmission of Sofdra NDA accepted by FDA

Botannix Pharmaceuticals' (ASX:BOT) resubmission of the new drug application for Sofdra has been accepted by the FDA as a complete response.

22 Jan 2024 12:04 (AEDT)

Botanix Pharmaceuticals completes HF validation study for Sofdra, eyes FDA approval by mid-2024

Botanix Pharmaceuticals (ASX:BOT) has completed the planned human factors (HF) validation study for Sofdra, evaluating revised instructions for use (IFU).

14 Dec 2023 11:53 (AEDT)

FDA greenlights Botanix Pharmaceuticals' Sofdra resubmission plan

FDA approves Botanix's strategy for Sofdra NDA resubmission with no additional materials requested, keeping submission to Q1 CY2024.

04 Dec 2023 10:08 (AEDT)

Botanix Pharmaceuticals successfully closes $13.5m Placement to boost US commercial activities

Botanix Pharmaceuticals (ASX: BOT) has closed its $13.5 million placement to both new and existing institutional and sophisticated investors to accelerate commercial activities in the US to increase revenue turnaround.

01 Dec 2023 11:50 (AEDT)

Botanix Pharmaceuticals (ASX:BOT) suffers setback in FDA approval for sofpironium bromide gel to treat hyperhidrosis

Botanix Pharmaceuticals (ASX:BOT) has had its application to use the novel sofpironium bromide gel to treat primary axillary hyperhidrosis rejected by the US FDA.

26 Sep 2023 16:36 (AEST)

Botanix Pharmaceuticals (ASX:BOT) appoints Dr Howie McKibbon as CEO

Botanix Pharmaceuticals (ASX:BOT) has appointed Dr Howie McKibbon as its newest Chief Executive Officer, effective from August 24. 

25 Aug 2023 11:17 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
14.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $284.3M
Open High Low Value Volume
14.5¢ 14.5¢ 14.0¢ $409.9K 2.900M

Buyers (Bids)

No. Vol. Price($)
97 3630156 14.0¢
 

Sellers (Offers)

Price($) Vol. No.
14.5¢ 1161424 14
View Market Depth
Last trade - 16.10pm 21/08/2025 (20 minute delay) ?
BOT (ASX) Chart

Top Stories

Vault Minerals CEO to exit – and investors don't seem at all bothered

Vault Minerals has rocketed after dropping news that the company's managing director and CEO, Luke Tonkin, will be stepping down.
Neurizon NUZ-001 OLE study demonstrates long-term safety, efficacy signals HotCopper sat down with Neurizon Therapeutics MD Michael Thurn to discuss the clinical-stage biotech company's latest NUZ-001 OLE study.
ASX Market Close: Index cracks 9,000pts and all-time high The ASX 200 has smashed through the big 9,000 mark for the first time ever, hitting a fresh all-time high of 9,013 in intraday trade.
ASX Market Open: We hit 9,000pts – and now traders not quite sure what to do | Aug 22 Many ASX traders seem to be more than a little stunned by hitting 9,000 yesterday, with many seeming to be avoiding making moves.
Listen: HotCopper Wire Podcast 021 – The inexplicable Kaili Resources rocket This week in the HotCopper Wire podcast we talk ASX earnings season, the +8,700% Kaili Resources rocket from Monday, and plenty more.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.